Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in advanced pancreatic neuroendocrine neoplasms (PanNENs) von Cowzer, Darren, Shah, Ronak H., Punn, Sippy, Fiedler, Laura, DeMore, April, Chou, Joanne F., Capanu, Marinela, Berger, Michael F., Reidy-Lagunes, Diane, Raj, Nitya Prabhakar

Volltext

Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience von Hauser, Haley, Le, Tiffany, Chou, Joanne F., Heffernan, Olivia, DeMore, April, Gonen, Selin, Capanu, Marinela, Reidy, Diane Lauren, Raj, Nitya Prabhakar

Volltext

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas von Raj, Nitya, Chan, Jennifer A., Wang, Stephanie J., Aggarwal, Rahul R., Calabrese, Susan, DeMore, April, Fong, Lawrence, Grabowsky, Jennifer, Hope, Thomas A., Kolli, Kanti Pallav, Mulvey, Claire K., Munster, Pamela N., Perez, Kimberly, Punn, Sippy, Reidy-Lagunes, Diane, Von Fedak, Sofia, Zhang, Li, Bergsland, Emily K.

Volltext

Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy) von Chan, Jennifer A., Raj, Nitya Prabhakar, Aggarwal, Rahul Raj, Calabrese, Susan, DeMore, April, Dhawan, Mallika Sachdev, Fattah, Delaire, Fong, Lawrence, Grabowsky, Jennifer, Hope, Thomas A, Kolli, Kanti Pallav, Munster, Pamela N., Perez, Kimberly, Reidy, Diane Lauren, Von Fedak, Sofia, Zhang, Li, Bergsland, Emily K.

Volltext

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors von Raj, Nitya, Cruz, Elizabeth, O'Shaughnessy, Sarah, Calderon, Claudia, Chou, Joanne F., Capanu, Marinela, Heffernan, Olivia, DeMore, April, Punn, Sippy, Le, Tiffany, Hauser, Haley, Saltz, Leonard, Reidy-Lagunes, Diane

Volltext